The release of positive clinical data typically leads to increased investor confidence in a biotech company's future prospects, which can result in a short-term rise in stock price. Given that the news is directly about Kura Oncology's clinical study results, it is highly relevant and important to the company's valuation. The confidence score reflects the typical market reaction to such news, although the long-term impact will depend on further results and regulatory approvals.